FIELD: organic chemistry.
SUBSTANCE: present invention refers to a compound of general formula (VI):
and its pharmaceutically acceptable salts. In formula (VI): R2A and R2B independently represent H, OH or C1-C4 alkyl, provided, that at least one of R2A and R2B is not H; R3 is C1-C4 fluoroalkyl, wherein said C1-C4 fluoroalkyl is optionally substituted with OH; R4 is H; R5A is SO2R7; R7 is C1-C4 alkyl. Also disclosed are a compound of formula (VI-B), 6-(difluoromethyl)-8-[(1R,2R)-2-hydroxy-2-methylcyclopentyl]-2-{[1-(methylsulphonyl)piperidin-4-yl]amino}pyrido[2,3-d]pyrimidin-7(8H)-one, a pharmaceutical composition, a method of treating cancer and use of said compounds for treating cancer.
EFFECT: obtaining novel organic compounds possessing the properties of a cyclin-dependent kinase (CDK) inhibitor suitable for treating cancer.
13 cl, 2 tbl, 226 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIPROLIFERATIVE AGENTS FOR THE TREATMENT OF PAH | 2020 |
|
RU2786588C1 |
| 3-CARBONYLAMINO-5-CYCLOPENTYL-1H-PYRAZOLE COMPOUNDS WITH CDK2 INHIBITOR ACTIVITY | 2020 |
|
RU2797889C2 |
| PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND ITS PHARMACEUTICALLY ACCEPTABLE SALT | 2017 |
|
RU2796400C2 |
| CYCLOALKANE-1,3-DIAMINE DERIVATIVE | 2019 |
|
RU2793247C2 |
| NEW PYRIDINE DERIVATIVE AND PYRIMIDINE DERIVATIVE (1) | 2005 |
|
RU2330021C2 |
| TRICYCLIC HETEROCYCLIC COMPOUNDS AND JAK INHIBITORS | 2012 |
|
RU2632870C2 |
| NEW COMPOUNDS AND THEIR PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF INFLAMMATORY DISEASES | 2018 |
|
RU2785126C2 |
| 2-AMINOPYRIDINE OR 2-AMINOPYRIMIDINE DERIVATIVES AS CYCLIN-DEPENDENT KINASE INHIBITORS | 2019 |
|
RU2790006C2 |
| DERIVATIVES OF 2-AMINOPYRIDINE OR 2-AMINOPYRIMIDINE AS CYCLIN-DEPENDENT KINASE INHIBITORS | 2019 |
|
RU2762557C1 |
| N-SUBSTITUTED DIOXOCYCLOBUTENYLAMINO-3-HYDROXYPICOLINAMIDES SUITABLE AS CCR6 INHIBITORS | 2019 |
|
RU2784831C2 |
